Nasal corticosteroids presents no ocular dangers in children

Article

Intermittent nasal corticosteroids do not cause ocular side effects such as cataract, glaucoma, corneal ectasia or abnormal tear function in children.

Intermittent nasal corticosteroids do not cause ocular side effects such as cataract, glaucoma, corneal ectasia or abnormal tear function in children, claims a study in Journal of Pediatric Ophthalmology & Strabismus.

A team managed by Dr Emin Ozayaka, Vakif Gureba Education and Research Hospital, Istanbul, Turkey, investigated a study group of 150 children who were administered intermittent intranasal budesonide for over two years. There were also 90 newly diagnosed allergic rhinitis patients included in the study who were not administered any treatment (control group).

The factors that were compared between the two groups were central corneal thickness, Schirmer test results, visual acuity, intraocular pressure, cataract formation, keratometry and tear break-up time.

The average steroid dosage was 93.3 ± 7.0 µg per day and 42.2 ± 3.2 g being the total steroid used during treatment. Of the 150 children included in the study group cataract formation, corneal ectasia, ocular hypertension and glaucoma were not found. Also, there was no correlation between the study group patients and total steroid dosage.

Treating children suffering from allergic rhinitis with intermittent intranasal budesonide at an average dose of 100 µg does not cause ocular defects.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.